Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/IIa Randomized, Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Antiviral Activity of BRII-179 (VBI-2601) among Subjects with Chronic Hepatitis B

Trial Profile

A Phase Ib/IIa Randomized, Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Antiviral Activity of BRII-179 (VBI-2601) among Subjects with Chronic Hepatitis B

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VBI 2601 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Proof of concept
  • Sponsors Brii Biosciences
  • Most Recent Events

    • 14 Nov 2019 According to VBI Vaccines media release, results from this study are expected in the second half of 2020.
    • 14 Nov 2019 According to VBI Vaccines media release, first patient dosed in this trial.
    • 06 Nov 2019 According to VBI Vaccines media release, VBI and Brii Bio plan to initiate the enrolment later in Q4 2019, which would enable an initial data readout in the second half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top